USD 4.23
(-10.19%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 619 Thousand USD | 92.58% |
2022 | 256 Thousand USD | 2744.44% |
2021 | 9000.00 USD | 103.09% |
2020 | -291 Thousand USD | -112.41% |
2019 | -137 Thousand USD | -126.65% |
2018 | 514 Thousand USD | 249.66% |
2017 | 147 Thousand USD | 228.95% |
2016 | -114 Thousand USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | 246 Thousand USD | 515.0% |
2024 Q2 | 358 Thousand USD | 66.67% |
2023 Q1 | -57 Thousand USD | -258.33% |
2023 Q3 | 344 Thousand USD | 96.57% |
2023 Q2 | 175 Thousand USD | 407.02% |
2023 FY | 493 Thousand USD | 92.58% |
2023 Q4 | 40 Thousand USD | -88.37% |
2022 Q3 | 148 Thousand USD | 46.53% |
2022 Q2 | 101 Thousand USD | 559.09% |
2022 Q1 | -22 Thousand USD | -121.15% |
2022 Q4 | 36 Thousand USD | -75.68% |
2022 FY | 256 Thousand USD | 2744.44% |
2021 Q4 | 104 Thousand USD | 282.46% |
2021 Q1 | -42 Thousand USD | 86.23% |
2021 Q2 | 4000.00 USD | 109.52% |
2021 Q3 | -57 Thousand USD | -1525.0% |
2021 FY | 9000.00 USD | 103.09% |
2020 Q2 | -85 Thousand USD | -226.87% |
2020 Q1 | 67 Thousand USD | 281.08% |
2020 Q4 | -305 Thousand USD | -1053.13% |
2020 FY | -291 Thousand USD | -112.41% |
2020 Q3 | 32 Thousand USD | 137.65% |
2019 Q2 | -66 Thousand USD | 38.89% |
2019 FY | -137 Thousand USD | -126.65% |
2019 Q4 | -37 Thousand USD | -150.0% |
2019 Q3 | 74 Thousand USD | 212.12% |
2019 Q1 | -108 Thousand USD | -193.1% |
2018 FY | 514 Thousand USD | 249.66% |
2018 Q3 | -10 Thousand USD | -103.51% |
2018 Q4 | 116 Thousand USD | 1260.0% |
2018 Q1 | 126 Thousand USD | -11.89% |
2018 Q2 | 285 Thousand USD | 126.19% |
2017 FY | 147 Thousand USD | 228.95% |
2017 Q4 | 143 Thousand USD | 0.0% |
2016 FY | -114 Thousand USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Akoya Biosciences, Inc. | 56.3 Million USD | 98.901% |
AngioDynamics, Inc. | 154.69 Million USD | 99.6% |
AtriCure, Inc. | 300.37 Million USD | 99.794% |
Avinger, Inc. | 2 Million USD | 69.096% |
Azenta, Inc. | 263.14 Million USD | 99.765% |
BioLife Solutions, Inc. | 46.75 Million USD | 98.676% |
The Cooper Companies, Inc. | 2.35 Billion USD | 99.974% |
Daxor Corporation | 1.1 Million USD | 43.903% |
Ekso Bionics Holdings, Inc. | 9.07 Million USD | 93.182% |
Femasys Inc. | 691.9 Thousand USD | 10.536% |
GlucoTrack, Inc. | -13 Thousand USD | 4861.538% |
Harvard Bioscience, Inc. | 60.86 Million USD | 98.983% |
Hologic, Inc. | 2.22 Billion USD | 99.972% |
ICU Medical, Inc. | 739.87 Million USD | 99.916% |
Intuitive Surgical, Inc. | 4.72 Billion USD | 99.987% |
KORU Medical Systems, Inc. | 16.7 Million USD | 96.295% |
LeMaitre Vascular, Inc. | 127.04 Million USD | 99.513% |
Innovative Eyewear, Inc. | -119.32 Thousand USD | 618.734% |
Innovative Eyewear, Inc. | -119.32 Thousand USD | 618.734% |
Masimo Corporation | 1 Billion USD | 99.938% |
Microbot Medical Inc. | -106 Thousand USD | 683.962% |
Meihua International Medical Technologies Co., Ltd. | 33.09 Million USD | 98.13% |
Merit Medical Systems, Inc. | 583.87 Million USD | 99.894% |
Nephros, Inc. | 8.4 Million USD | 92.635% |
NovoCure Limited | 381.05 Million USD | 99.838% |
NEXGEL, Inc. | 619 Thousand USD | 0.0% |
Singular Genomics Systems, Inc. | -558 Thousand USD | 210.932% |
OraSure Technologies, Inc. | 179.42 Million USD | 99.655% |
Pro-Dex, Inc. | 14.55 Million USD | 95.746% |
Pulse Biosciences, Inc. | -1.2 Million USD | 151.284% |
Predictive Oncology Inc. | 1.14 Million USD | 45.953% |
Precision Optics Corporation, Inc. | 5.79 Million USD | 89.323% |
QuidelOrtho Corporation | 1.49 Billion USD | 99.959% |
Repligen Corporation | 315.22 Million USD | 99.804% |
Sanara MedTech Inc. | 57.13 Million USD | 98.917% |
STAAR Surgical Company | 252.65 Million USD | 99.755% |
Sharps Technology, Inc. | -891.24 Thousand USD | 169.453% |
Utah Medical Products, Inc. | 30.03 Million USD | 97.939% |
DENTSPLY SIRONA Inc. | 2.08 Billion USD | 99.97% |
Jin Medical International Ltd. | 6.78 Million USD | 90.877% |